Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

Background Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid cells. S100A9 was previously identified as a key regulator of myel...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMJ Publishing Group 2023-01-01
סדרה:	Journal for ImmunoTherapy of Cancer
גישה מקוונת:	https://jitc.bmj.com/content/11/1/e005319.full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!